The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review

Akkaif, Mohammed Ahmed and Sha'aban, Abubakar and Cesaro, Arturo and Jaber, Ammar Ali Saleh and Vergara, Andrea and Yunusa, Ismaeel and Jatau, Abubakar Ibrahim and Mohammed, Mustapha and Govindasamy, G. Saravana and Al-Mansoub, Majed Ahmed and Kader, Muhamad Ali Sheikh Abdul and Ibrahim, Baharudin (2022) The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review. Inflammopharmacology, 30 (4). pp. 1143-1151. ISSN 0925-4692, DOI

Full text not available from this repository.


The coronavirus disease-2019 (COVID-19) pandemic has become a major global health problem. COVID-19 is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and exhibits pulmonary and extrapulmonary effects, including cardiovascular involvement. There are several attempts to identify drugs that could treat COVID-19. Moreover, many patients infected with COVID-19 have underlying diseases, particularly cardiovascular diseases. These patients are more likely to develop severe illnesses and would require optimized treatment strategies. The current study gathered information from various databases, including relevant studies, reviews, trials, or meta-analyses until April 2022 to identify the impact of SARS-CoV-2 treatment on the cardiovascular system. Studies have shown that the prognosis of patients with underlying cardiovascular disease is worsened by COVID-19, with some COVID-19 medications interfering with the cardiovascular system. The COVID-19 treatment strategy should consider many factors and parameters to avoid medication-induced cardiac injury, mainly in elderly patients. Therefore, this article provides a synthesis of evidence on the impact of different COVID-19 medications on the cardiovascular system and related disease conditions.

Item Type: Article
Funders: Discipline of Clinical Pharmacy, School of Pharmaceutical Science, Universiti Sains Malaysia
Uncontrolled Keywords: Cardiovascular diseases; SARS-CoV-2; COVID-19; Drug development
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Pharmacy > Department of Clinical Pharmacy and Pharmacy Practice
Depositing User: Ms. Juhaida Abd Rahim
Date Deposited: 19 Oct 2023 03:57
Last Modified: 19 Oct 2023 03:57

Actions (login required)

View Item View Item